Login / Signup

Evaluation of mavacamten in patients with hypertrophic cardiomyopathy.

Hui-Ling LiaoYi LiangBo Liang
Published in: Journal of cardiovascular medicine (Hagerstown, Md.) (2024)
Mavacamten demonstrates both safety and efficacy in patients with HCM, suggesting its potential as a promising therapeutic strategy for this condition. Further research is warranted to confirm these results and explore its long-term effects.
Keyphrases
  • hypertrophic cardiomyopathy
  • left ventricular
  • heart failure